<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108025</url>
  </required_header>
  <id_info>
    <org_study_id>DMT310-005</org_study_id>
    <nct_id>NCT05108025</nct_id>
  </id_info>
  <brief_title>DMT310-005 Topical in the Treatment of Acne Rosacea</brief_title>
  <official_title>A Study Of The Tolerability, Safety, And Efficacy Of DMT310 For The Treatment Of Acne Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermata Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermata Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder&#xD;
      mixed with diluent in male and female patients with moderate to severe facial acne rosacea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy as measured by lesion counts</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Inflammatory lesion counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy as measured by Investigator Global Assessment (IGA)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>IGA Scale:&#xD;
0 Clear No papules and/or pustules&#xD;
Almost Clear Rare papules and/or pustules&#xD;
Mild Few papules and/or pustules&#xD;
Moderate Pronounced number of papules and/or pustules (but less than numerous papules and/or pustules)&#xD;
Severe Numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events as a measure of safety and tolerability</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Incidence of adverse events as a measure of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Acne Rosacea</condition>
  <arm_group>
    <arm_group_label>Study Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DMT310 Powder mixed with Hydrogen Peroxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo powder mixed with Hydrogen Peroxide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Powder</intervention_name>
    <description>Topical Powder mixed with diluent</description>
    <arm_group_label>Study Treatment 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Topical Powder</intervention_name>
    <description>Placebo Topical Powder mixed with diluent</description>
    <arm_group_label>Study Treatment 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient is male or non-pregnant female at least 18 years of age.&#xD;
&#xD;
        Clinical diagnosis of moderate to severe papulopustular acne rosacea as determined by:&#xD;
&#xD;
        Investigator's Global Assessment (IGA) at Randomization score of 3 or 4. Patient has at&#xD;
        least 15 inflammatory lesions on the face&#xD;
&#xD;
        Patient is willing to apply the Investigational Product as directed&#xD;
&#xD;
        Patient is willing and able to comply with the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient is pregnant or planning to become pregnant Patient is taking a topical therapy on&#xD;
        the face which may affect the patient's rosacea&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dermata Study Director</last_name>
    <phone>858-800-2543</phone>
    <phone_ext>703</phone_ext>
    <email>clinicaltrial@dermatarx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dermata Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

